Volume Spike Investor

Protalix BioTherapeutics Inc. (NYSE: PLX) shares are up 27 percent on volume of about 33,000 shares (half its daily average near the open) after the company said the FDA wants it to submit a treatment protocol for its experimental Gaucher disease drug to help offset a likely shortage of a Genzyme Corp.’s (Nasdaq: GENZ) Cerezyme drug.

Genzyme plans to temporarily shut down its production plant for Cerezyme to clean up a virus contamination. — Mike Tarsala

See related post.